

Mauro Andreotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/80814/publications.pdf>

Version: 2024-02-01

97
papers

2,004
citations

257450

24
h-index

276875

41
g-index

99
all docs

99
docs citations

99
times ranked

2854
citing authors

#	ARTICLE	IF	CITATIONS
1	UltraViolet SANitizing System for Sterilization of Ambulances Fleets and for Real-Time Monitoring of Their Sterilization Level. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 331.	2.6	8
2	Seroprevalence of Brucella Infection in a Cohort of HIV-Positive Malawian Pregnant Women Living in Urban Areas. <i>Vector-Borne and Zoonotic Diseases</i> , 2022, , .	1.5	1
3	Immunoglobulin G passive transfer from mothers to infants: total IgG, IgG subclasses and specific antipneumococcal IgG in 6-week Malawian infants exposed or unexposed to HIV. <i>BMC Infectious Diseases</i> , 2022, 22, 342.	2.9	3
4	Isolation and preliminary characterization of a human ϕ phage display TM -derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding. <i>Human Antibodies</i> , 2021, 29, 63-84.	1.5	2
5	Dried blood spots for the quantitative evaluation of IgG isotypes and correlation with serum samples in HIV-exposed uninfected (HEU) infants. <i>Journal of Immunological Methods</i> , 2021, 493, 113019.	1.4	4
6	HIV-exposed infants with EBV infection have a reduced persistence of the immune response to the HBV vaccine. <i>AIDS Research and Therapy</i> , 2021, 18, 48.	1.7	3
7	Diagnostic accuracy of dried plasma spot specimens for HIV-1 viral load testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	2.1	3
8	Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia. <i>JAMA Network Open</i> , 2021, 4, e2136246.	5.9	50
9	Transcriptome Profiling of Human Monocyte-Derived Macrophages Upon CCL2 Neutralization Reveals an Association Between Activation of Innate Immune Pathways and Restriction of HIV-1 Gene Expression. <i>Frontiers in Immunology</i> , 2020, 11, 2129.	4.8	7
10	Low mortality rates at two years in HIV-infected individuals undergoing systematic tuberculosis testing with rapid assays at initiation of antiretroviral treatment in Mozambique. <i>International Journal of Infectious Diseases</i> , 2020, 99, 386-392.	3.3	0
11	<i>In vivo</i> antiaging effects of alkaline water supplementation. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 657-664.	5.2	10
12	Dynamics of immunoglobulin G subclasses during the first two years of life in Malawian infants born to HIV-positive mothers. <i>BMC Pediatrics</i> , 2020, 20, 181.	1.7	6
13	Beneficial Effects of Fermented Papaya Preparation (FPP [®]) Supplementation on Redox Balance and Aging in a Mouse Model. <i>Antioxidants</i> , 2020, 9, 144.	5.1	12
14	Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion. <i>BMC Biotechnology</i> , 2019, 19, 67.	3.3	15
15	IgG abnormalities in HIV-positive Malawian women initiating antiretroviral therapy during pregnancy persist after 24 months of treatment. <i>International Journal of Infectious Diseases</i> , 2019, 88, 1-7.	3.3	4
16	Plasma levels of CRP, neopterin and IP-10 in HIV-infected individuals with and without pulmonary tuberculosis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2019, 16, 100107.	1.3	9
17	Immune Activation and Microbial Translocation Markers in HIV-Exposed Uninfected Malawian Infants in the First Year of Life. <i>Journal of Tropical Pediatrics</i> , 2019, 65, 617-625.	1.5	6
18	Performance of Cepheid Xpert HIV-1 viral load plasma assay to accurately detect treatment failure. <i>Aids</i> , 2019, 33, 1881-1889.	2.2	14

#	ARTICLE	IF	CITATIONS
19	Soluble <scp>CD</scp> 14 levels in plasma and breastmilk of Malawian <scp>HIV</scp> + women: Lack of association with morbidity and mortality in their exposed infants. American Journal of Reproductive Immunology, 2018, 79, e12812.	1.2	4
20	Deficit of IgG2 in HIV-positive pregnant women is responsible of inadequate IgG2 levels in their HIV-uninfected children in Malawi. Medical Microbiology and Immunology, 2018, 207, 175-182.	4.8	3
21	Antibody response to hepatitis B vaccine in HIV-exposed infants in Malawi and correlation with HBV infection acquisition. Journal of Medical Virology, 2018, 90, 1172-1176.	5.0	5
22	APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz. Frontiers in Immunology, 2018, 9, 1839.	4.8	11
23	Lack of new HBV infections over 2 years of follow-up in HIV-positive women receiving ART up to 6 or 24 months after delivery. Journal of Infection in Developing Countries, 2018, 12, 394-396.	1.2	0
24	Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy. Clinical Microbiology and Infection, 2017, 23, 491-492.	6.0	3
25	Hepatitis E virus infection in HIV-infected pregnant women and their children in Malawi. Infectious Diseases, 2017, 49, 708-711.	2.8	8
26	Trans-dissemination of exosomes from HIV-1-infected cells fosters both HIV-1 trans-infection in resting CD4+ T lymphocytes and reactivation of the HIV-1 reservoir. Archives of Virology, 2017, 162, 2565-2577.	2.1	11
27	Probiotic supplementation promotes a reduction in T cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-positive patients. Immunity, Inflammation and Disease, 2017, 5, 244-260.	2.7	84
28	High CMV IgG antibody levels are associated to a lower CD4+ RESPONSE to antiretroviral therapy in HIV-infected women. Journal of Clinical Virology, 2017, 96, 17-19.	3.1	3
29	Tuberculosis Case Finding With Combined Rapid Point-of-Care Assays (Xpert MTB/RIF and Determine TB) Tj ETQq1 1 0.784314 rgBT /Ov Diseases, 2017, 65, 1878-1883.	5.8	42
30	CMV infection in a cohort of HIV-exposed infants born to mothers receiving antiretroviral therapy during pregnancy and breastfeeding. Medical Microbiology and Immunology, 2017, 206, 23-29.	4.8	7
31	Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. Journal of Antimicrobial Chemotherapy, 2016, 71, 1027-1030.	3.0	32
32	Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. AIDS Research and Human Retroviruses, 2016, 32, 737-742.	1.1	9
33	Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi. Journal of Antimicrobial Chemotherapy, 2016, 71, 3206-3211.	3.0	5
34	Serum Phosphate and Creatinine Levels in the First Year of Life in Infants Born to HIV-Positive Mothers Receiving Tenofovir-Based Combination Regimens During Pregnancy and Prolonged Breastfeeding in an Option B+ Program in Malawi. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, e90-e91.	2.1	0
35	Retention, transfer out and loss to follow-up two years after delivery in a cohort of HIV+ pregnant women in Malawi. International Journal of STD and AIDS, 2016, 27, 462-468.	1.1	8
36	Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. Infectious Diseases, 2016, 48, 317-321.	2.8	6

#	ARTICLE	IF	CITATIONS
37	Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection. <i>Journal of Virological Methods</i> , 2016, 229, 35-39.	2.1	53
38	Analysis of Th17 and Tc17 Frequencies and Antiviral Defenses in Gut-Associated Lymphoid Tissue of Chronic HIV-1 Positive Patients. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	3.0	15
39	Measurement of viral load by the automated Abbott real-time HIV-1 assay using dried blood spots collected and processed in Malawi and Mozambique. <i>South African Medical Journal</i> , 2015, 105, 1036.	0.6	14
40	Laboratory confirmation of clinically diagnosed malaria in a cohort of HIV-infected mothers and their children in Malawi. <i>Journal of Tropical Pediatrics</i> , 2015, 61, 222-225.	1.5	0
41	Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2881-2884.	3.0	4
42	Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. <i>Retrovirology</i> , 2015, 12, 4.	2.0	35
43	Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. <i>Journal of Viral Hepatitis</i> , 2015, 22, 289-296.	2.0	13
44	Anti- <i>Streptococcus pneumoniae</i> and rotavirus IgG levels in HIV-positive women do not correlate with maternal status and infant morbidity and mortality. <i>Journal of Medical Microbiology</i> , 2015, 64, 795-797.	1.8	2
45	Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. <i>Aids</i> , 2015, 30, 1.	2.2	8
46	Viral Sequence Analysis of HIV-Positive Women and Their Infected Children: Insight on the Timing of Infection and on the Transmission Network. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1010-1015.	1.1	4
47	Recovery of Interleukin-17 Production from Interleukin-15-Stimulated CD4+ Mononuclear Cells in HIV-1-Infected Patients with Sustained Viral Suppression. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 35-40.	1.2	4
48	Weight Changes During and After 6 Months of Breastfeeding in HIV-Infected Mothers Receiving Antiretroviral Therapy in Malawi. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1155-1157.	1.1	1
49	Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 749-752.	3.0	2
50	The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi. <i>BMC Infectious Diseases</i> , 2014, 14, 180.	2.9	12
51	Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e109791.	2.5	26
52	Targeting CCL2 inhibits viral DNA accumulation and induces APOBEC3A expression in HIV-1 infected primary human macrophages. <i>Retrovirology</i> , 2013, 10, .	2.0	0
53	HIV-1 coreceptor switch during 2 years of structured treatment interruptions. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1565-1570.	2.9	4
54	Effects of Raltegravir on 2-Long Terminal Repeat Circle Junctions in HIV Type 1 Viremic and Aviremic Patients. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1365-1369.	1.1	2

#	ARTICLE	IF	CITATIONS
55	Maternal Antiretroviral Therapy for the Prevention of Mother-To-Child Transmission of HIV in Malawi: Maternal and Infant Outcomes Two Years after Delivery. <i>PLoS ONE</i> , 2013, 8, e68950.	2.5	56
56	Antiretroviral Prophylaxis for Breastfeeding Transmission in Malawi: Drug Concentrations, Virological Efficacy and Safety. <i>Antiviral Therapy</i> , 2012, 17, 1511-1519.	1.0	37
57	The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. <i>Cytokine</i> , 2012, 57, 54-60.	3.2	6
58	Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi. <i>Journal of Medical Virology</i> , 2012, 84, 1553-1557.	5.0	13
59	HIV Persistence in the Gut Mucosa of HIV-Infected Subjects Undergoing Antiretroviral Therapy Correlates with Immune Activation and Increased Levels of LPS. <i>Current HIV Research</i> , 2011, 9, 148-153.	0.5	68
60	Limited Risk of Drug Resistance After Discontinuation of Antiretroviral Prophylaxis for the Prevention of Breastfeeding Transmission of HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 301-304.	2.1	2
61	Quantification of HIV-RNA from dried blood spots using the Siemens VERSANT(R) HIV-1 RNA (kPCR) assay. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2823-2826.	3.0	15
62	Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 541-545.	1.1	7
63	Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. <i>Journal of Clinical Virology</i> , 2010, 47, 4-7.	3.1	45
64	Comparison of HIV Type 1 Sequences from Plasma, Cell-Free Breast Milk, and Cell-Associated Breast Milk Viral Populations in Treated and Untreated Women in Mozambique. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 707-711.	1.1	9
65	Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions. <i>Journal of Medical Microbiology</i> , 2009, 58, 121-124.	1.8	1
66	DC contact with HIV-1-infected cells leads to high levels of Env-mediated virion endocytosis coupled with enhanced HIV-1 Ag presentation. <i>European Journal of Immunology</i> , 2009, 39, 404-416.	2.9	7
67	The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. <i>HIV Medicine</i> , 2009, 10, 477-481.	2.2	11
68	Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with ≥ 50copies/ml HIV-1 RNA. <i>Journal of Clinical Virology</i> , 2009, 46, 367-370.	3.1	54
69	Novel Quinolinonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, and Biological Activities. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4744-4750.	6.4	45
70	HIV-1 Residual Viremia and Proviral DNA in Patients with Suppressed Plasma Viral Load (≤ 400 copies/ml). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 57, 107-111.	0.5	31
71	Single-nucleotide polymorphisms in human $\beta 2$ -defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. <i>Aids</i> , 2008, 22, 1515-1517.	2.2	33
72	Tumor Necrosis Factor- α , Interleukin-10, and $\beta 2$ -Defensins in Plasma and Breast Milk of HIV-Infected Highly Active Antiretroviral Therapy-Treated and Untreated Pregnant Women in Mozambique. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 647-649.	2.1	5

#	ARTICLE	IF	CITATIONS
73	Modifications of HIV-1 DNA and Provirus-Infected Cells During 24 Months of Intermittent Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 68-71.	2.1	4
74	Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained HIV Load Suppression: Four Years of Follow-up. <i>HIV Clinical Trials</i> , 2007, 8, 182-188.	2.0	6
75	Triple Antiretroviral Prophylaxis Administered During Pregnancy and After Delivery Significantly Reduces Breast Milk Viral Load. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 44, 286-291.	2.1	61
76	Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. <i>Aids</i> , 2007, 21, 2360-2362.	2.2	10
77	HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. <i>Retrovirology</i> , 2007, 4, 17.	2.0	20
78	Determinants of Virologic and Immunologic Outcomes in Chronically HIV-Infected Subjects Undergoing Repeated Treatment Interruptions. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 46, 39-47.	2.1	36
79	Novel Bifunctional Quinolonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, Biological Activities, and Mechanism of Action. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1939-1945.	6.4	82
80	Interleukin-15 enhances the secretion of IFN- β and CC chemokines by natural killer cells from HIV viremic and aviremic patients. <i>Immunology Letters</i> , 2006, 103, 192-195.	2.5	19
81	IFN- α -conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens. <i>European Journal of Immunology</i> , 2006, 36, 2046-2060.	2.9	132
82	Development of a Human Immunodeficiency Virus Vector-Based, Single-Cycle Assay for Evaluation of Anti-Integrase Compounds. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3407-3417.	3.2	18
83	Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. <i>Aids</i> , 2005, 19, 1843-1847.	2.2	47
84	Association between Cellular Human Immunodeficiency Virus DNA Level and Immunological Parameters in Patients with Undetectable Plasma Viremia Level during Highly Active Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2005, 43, 6183-6185.	3.9	21
85	Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy. <i>Clinical and Experimental Immunology</i> , 2004, 135, 280-285.	2.6	9
86	Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mm ³). <i>HIV Medicine</i> , 2004, 5, 1-10.	2.2	17
87	IFN- α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. <i>Blood</i> , 2004, 103, 980-987.	1.4	68
88	Vav exchange factor counteracts the HIV-1 Nef-mediated decrease of plasma membrane GM1 and NF-AT activity in T cells. <i>European Journal of Immunology</i> , 2003, 33, 2186-2196.	2.9	12
89	Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN- α . <i>Journal of Experimental Medicine</i> , 2003, 198, 361-367.	8.5	130
90	Monocyte-Derived Dendritic Cells Generated After a Short-Term Culture with IFN- α and Granulocyte-Macrophage Colony-Stimulating Factor Stimulate a Potent Epstein-Barr Virus-Specific CD8+ T Cell Response. <i>Journal of Immunology</i> , 2003, 170, 5195-5202.	0.8	79

#	ARTICLE	IF	CITATIONS
91	Discordant response to antiretroviral therapy. <i>Aids</i> , 2002, 16, 1877-1885.	2.2	18
92	HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/uL): an analysis of 338 clinical events from a randomized clinical trial*. <i>HIV Medicine</i> , 2002, 3, 75-84.	2.2	22
93	Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. <i>Aids</i> , 2000, 14, 251-261.	2.2	86
94	Quality of life outcomes of combination zidovudine+didanosine+nevirapine and zidovudine+didanosine for antiretroviral-naive advanced HIV-infected patients. <i>Aids</i> , 2000, 14, 2567-2574.	2.2	24
95	Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment ¹ . <i>Antiviral Research</i> , 2000, 47, 189-198.	4.1	13
96	Hospitalizations and Costs of Treatment for Protease Inhibitor-Based Regimens in Patients with Very Advanced HIV-Infection (CD4 < 50/mm ³). <i>HIV Clinical Trials</i> , 2000, 1, 9-16.	2.0	12
97	A Randomized Trial Comparing the Introduction of Ritonavir or Indinavir in 1251 Nucleoside-Experienced Patients with Advanced HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1809-1820.	1.1	9